Global Biosimilars Insulin Sales Data & Market Report 2020 and Forecast 2021-2026
- TBI756781
- January 21, 2021
- Global
- 144 pages
- SAC Insights
A recently concluded research by Trusted Business Insights titled Global Biosimilars Insulin Sales Market Report 2020 will enable in acquiring a holistic view of overall market scenario and it’s most lucrative sectors. The research report provides quality data in a business and management reporting format. It examines the historic accomplishments and recent opportunities present in the global Biosimilars Insulin market. Trusted Business Insights report focuses on the consumption, geography, by type, by application, and the competitive landscape. This report splits the data for each region to analyze the leading companies, applications, and product types.
Trusted Business Insights aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview: Biosimilars Insulin Market
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
The global Biosimilars Insulin market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
The global Biosimilars Insulin market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilars Insulin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheims biosimilar insulin glargine has got approval through European Medicines Agencys (EMAs) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
Geographical Analysis: Biosimilars Insulin Market
Based on region, the global Biosimilars Insulin market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players: Biosimilars Insulin Market
The major players that are operating in the global Biosimilars Insulin market are
Segment by Type Biosimilars Insulin Market
- Insulin Glargine Basaglar
- Insulin Lantus
Segment by Application Biosimilars Insulin Market
- Type I Diabetes
- Type II Diabetes
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Biosimilars Insulin market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Biosimilars Insulin market.
• The market share of the global Biosimilars Insulin market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Biosimilars Insulin market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Biosimilars Insulin market.
This research comprehensively answers the following 9 important questions:
- Q.1. What are some of the most promising growth trends in the Biosimilars Insulin market worldwide?
- Q.2.Which segments and sub-segments will grow at a faster pace and why? Which segment is nearing the peak and demand saturation?
- Q.3.Which region will witness a higher growth rate and why? Which region might see a slower or negative growth region?
- Q.4.What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in the Biosimilars Insulin market?
- Q.5.What are the business risks and who pose challenges to the global leaders and are competitive threats in this Biosimilars Insulin market?
- Q.6.What are the emerging trends post COVID-19 reshuffle in this Biosimilars Insulin market and the what are reasons behind these trends and do they translate in global exploration?
- Q.7. Who are the major global and regional players in the Biosimilars Insulin market? Which are the strategic initiatives key players are pursuing for business growth?
- Q.8.Which are the competing products in the Biosimilars Insulin market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.9.What M & A activity has occurred in the last 5 years and what is its impact on the Biosimilars Insulin industry?
Chapter 1 Methodology and Scope
1.1 Information Procurement
1.1.1 Purchased Database
1.1.2 Trusted Business Insights Internal Database
1.1.3 Secondary Sources
1.1.4 Third-Party Perspective
1.1.5 Primary Research
1.2 Information Analysis & Data Analysis Models
1.3 List of Data Sources
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Market Outlook
2.3 Segmental Outlook
2.4 Segmental Outlook (Continued)
2.5 Competitive Insights
Chapter 3Biosimilars Insulin Market: Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Outlook On Application Market
3.2 Penetration & Growth Prospect Mapping
3.3 Industry Value Chain Analysis
3.3.1 Raw Material Trends
3.3.2 Manufacturing Trends
...
| read more...
